Sartorius Stedim Biotech Release: New Poster On The Ambr 15 Fermentation Micro Scale Bioreactor System
Presents data showing how the system can be used to support batch and high density fed batch microbial screening
Cambridge, UK – 12 May, 2016: Sartorius Stedim Biotech (SSB) today announced a poster presented at BPI Europe, entitled, ‘A novel automated micro bioreactor for high density fed batch microbial screening applications’ is now available online. The poster details how scientists at SSB assessed the new ambr® 15 fermentation system as a model for benchtop bioreactors to support development of batch and high density fed-batch microbial cultures.
The poster presents oxygen transfer rates, dissolved oxygen (DO) and pH control data from E.coli batch cultured in the ambr15 fermentation system, which consists of 24 single-use, stirred micro bioreactors integrated to an automated workstation. These results show that the pH and gas flow in the ambr15 fermentation micro bioreactors (8-12mL working volume) are tightly controlled and can achieve a KLa of approximately 380 h-1, which is comparable to the oxygen transfer rate generated in a production scale bioreactor.
The poster also details scale-up data from E. coli cultured in a fed-batch process in ambr15 fermentation micro bioreactors, a 1L Dasgip benchtop bioreactor and an SSB ambr 250 (250 mL) mini bioreactor. The results demonstrate that the growth profiles from all three bioreactor types have good comparability and high density cultures with an OD600 > 150 can be achieved in the ambr15 fermentation micro bioreactor.
To request free access to this poster, scientists should click the link: http://www.tapbiosystems.com/ambr15f_emailer/ambr15fpostreqSSB.php
Dr. Barney Zoro, ambr15 fermentation Product Manager, at SSB commented: “An automated micro bioreactor system needs to have a combination of tightly controlled pH and DO, semi-continuous feed supply and the right type of culture agitation to provide consistent, reproducible and predictive results.”
Zoro adds: “The data in our poster indicates that the ambr15 fermentation system easily achieves these parameters, showing scientists how they could replace their shake flasks and bench top bioreactors with a micro bioreactor to significantly increase throughput of their microbial strain selection studies.”
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of “turning science into solutions.”
Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx. 3,700 people, and in 2014 earned sales revenue of 683.5 million euros.
ambr® systems are designed and manufactured by TAP Biosystems (now part of the Sartorius Stedim Biotech Group) a leading global provider of automated cell culture and fermentation systems for life science research, development and production. ambr systems are widely used for cell line development and process optimisation at pharmaceutical, biotechnology and academic laboratories. They are proven to provide a reliable model and consistent scalability to a range of upstream processes.
Cambridge, UK – 12 May, 2016: Sartorius Stedim Biotech (SSB) today announced a poster presented at BPI Europe, entitled, ‘A novel automated micro bioreactor for high density fed batch microbial screening applications’ is now available online. The poster details how scientists at SSB assessed the new ambr® 15 fermentation system as a model for benchtop bioreactors to support development of batch and high density fed-batch microbial cultures.
The poster presents oxygen transfer rates, dissolved oxygen (DO) and pH control data from E.coli batch cultured in the ambr15 fermentation system, which consists of 24 single-use, stirred micro bioreactors integrated to an automated workstation. These results show that the pH and gas flow in the ambr15 fermentation micro bioreactors (8-12mL working volume) are tightly controlled and can achieve a KLa of approximately 380 h-1, which is comparable to the oxygen transfer rate generated in a production scale bioreactor.
The poster also details scale-up data from E. coli cultured in a fed-batch process in ambr15 fermentation micro bioreactors, a 1L Dasgip benchtop bioreactor and an SSB ambr 250 (250 mL) mini bioreactor. The results demonstrate that the growth profiles from all three bioreactor types have good comparability and high density cultures with an OD600 > 150 can be achieved in the ambr15 fermentation micro bioreactor.
To request free access to this poster, scientists should click the link: http://www.tapbiosystems.com/ambr15f_emailer/ambr15fpostreqSSB.php
Dr. Barney Zoro, ambr15 fermentation Product Manager, at SSB commented: “An automated micro bioreactor system needs to have a combination of tightly controlled pH and DO, semi-continuous feed supply and the right type of culture agitation to provide consistent, reproducible and predictive results.”
Zoro adds: “The data in our poster indicates that the ambr15 fermentation system easily achieves these parameters, showing scientists how they could replace their shake flasks and bench top bioreactors with a micro bioreactor to significantly increase throughput of their microbial strain selection studies.”
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of “turning science into solutions.”
Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx. 3,700 people, and in 2014 earned sales revenue of 683.5 million euros.
ambr® systems are designed and manufactured by TAP Biosystems (now part of the Sartorius Stedim Biotech Group) a leading global provider of automated cell culture and fermentation systems for life science research, development and production. ambr systems are widely used for cell line development and process optimisation at pharmaceutical, biotechnology and academic laboratories. They are proven to provide a reliable model and consistent scalability to a range of upstream processes.